Alaproclate
Alaproclate is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB in the 1970s.
It acts as a selective serotonin reuptake inhibitor, and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in animal [testing on rodents|rodent studies]. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.
The drug is similar in chemical structure to chlorphentermine, cloforex, and cericlamine, but is not itself a phenethylamine or amphetamine as it has an oxygen atom in place of the amine nitrogen.
Alaproclate was first described in the scientific literature by 1978.